STOCK COMPARISON
Orion Oyj B vs Eli Lilly and: Fair Value & Quality
Both stocks run through our valuation models. Here is how Orion Oyj B (ORNBV) and Eli Lilly and (LLY) compare, as of Aug 8, 2026.
As of Aug 8, 2026, Fair Value Calculator sees Orion Oyj B as the less overvalued of the two: Orion Oyj B trades at €81.60 versus a fair value of €53.64 (-34%), while Eli Lilly and trades at $1,192 versus $397 (-67%).
Orion Oyj B
ORNBV.HE · EUR · Health Care
-34%
upside to fair value
overvalued
Price€81.60
Fair Value€53.64
Quality76/100
Eli Lilly and
LLY · USD · Health Care
-67%
upside to fair value
overvalued
Price$1,192
Fair Value$397
Quality75/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Orion Oyj BEli Lilly and
Valuation
18.5×P/E (TTM)42.2×
6.11×P/S (TTM)14.67×
9.79×P/B39.94×
15.8×EV/EBITDA30.2×
5.73×PEG1.54×
2.6%Dividend yield0.5%
€1.80Dividend per share$6.23
Profitability
29%Net margin35%
34%Operating margin49%
54%Return on equity107%
26%Return on assets21%
Growth
25%Revenue growth (YoY)56%
12.1%Avg. growth/yr (3Y)31.7%
11.9%Avg. growth/yr (5Y)21.6%
Balance & size
0.08×Debt / equity1.54×
$13BMarket cap$1.1T
mixedGrowth qualitymixed
Even match: 7 to 7 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Orion Oyj Bof which business quality 73 · market factors 68
Eli Lilly andof which business quality 65 · market factors 81
ProfitabilityMargins and returns on capital today
94
85
Quality GrowthAre margins and returns improving?
73
86
CashflowEarnings quality: real cash, not paper profit
46
51
Fin. StrengthBalance sheet, leverage, solvency risk
83
53
InvestmentDisciplined investing over empire-building
57
15
Low VolatilityCalm price path (market factor)
80
73
MomentumPrice trend over the last 3–12 months (market factor)
55
78
52W MomentumDistance to the 52-week high (market factor)
77
94
Net IssuanceBuybacks instead of dilution
81
93
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Orion Oyj B
DCF Models€48.36
Earnings-Based€30.01
Dividend Discount€27.65
Multiples€48.99
Asset-Based€6.12
Growth DCF€29.81
Economic Profit€38.43
Growth Earnings€61.28
26 of 26 models see the stock below the current price.
Eli Lilly and
DCF Models$323
Earnings-Based$239
Dividend Discount$115
Multiples$303
Asset-Based$19.94
Growth DCF$171
Economic Profit$347
Growth Earnings$353
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Orion Oyj B
Bear €31.53Fair Value €53.64Bull €84.60
€81.60 = current price (white tick)
Eli Lilly and
Bear $222Fair Value $397Bull $582
$1,192 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Orion Oyj B · Health Care
Quality score76 · Top 25%
Fair value upside-34% · below median
Eli Lilly and · Health Care
Quality score75 · Top 25%
Fair value upside-67% · bottom 25%
Bottom line
As of Aug 8, 2026, Fair Value Calculator sees Orion Oyj B as the less overvalued of the two: Orion Oyj B trades at €81.60 versus a fair value of €53.64 (-34%), while Eli Lilly and trades at $1,192 versus $397 (-67%).
Orion Oyj B has the higher quality score (76/100).
See the full analysis →
More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Free · Top-25 report
See the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
